Autres langues Spruce Biosciences, Inc.

Actions

SPRB

US85209E1091

Temps réel estimé Cboe BZX Autres places de cotation 16:37:15 19/04/2024			Varia. 5j.	Varia. 1 janv.
0,7 ^USD	-0,14 %		-4,92 %	-76,11 %

14/03	Les plus fortes baisses de la mi-journée	MT
14/03	Mise à jour sectorielle : Les actions du secteur de la santé en baisse jeudi après-midi	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB	05/04
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB	27/03
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	21/03
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB	19/03
North American Morning Briefing : Inflation -2-	15/03
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	14/03
Top Midday Decliners	14/03
Sector Update: Health Care Stocks Lower Thursday Afternoon	14/03
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	14/03
Spruce Biosciences 2023 Loss Narrows; to Cut 21% Workforce After Trial Misses Target; Shares Sink	13/03
Spruce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates	13/03
Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH	13/03
Spruce Biosciences, Inc. Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH	13/03
Top Premarket Decliners	13/02
Spruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	30/01
Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia	22/01
Spruce Biosciences, Inc. Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia	22/01
SPRUCE BIOSCIENCES REPORTS BASELINE CHARACTERISTICS FROM CAHMELIA-203 AND CAHMELIA-204 STUDIES IN ADULT CLASSIC CAH	08/01
Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH	05/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Spruce Biosciences, Inc.

Actions

SPRB

US85209E1091

Autres langues

Filtres